The Filing Desk

Absci vs Inhibrx Biosciences

Absci ABSI · Inhibrx Biosciences INBX · Biotechnology

Absci reported revenue of $3 million in fiscal 2025, 2.2 times Inhibrx Biosciences' $1 million in fiscal 2025. Absci's revenue fell 38.2% in its latest year, and Inhibrx Biosciences' grew 550.0%. Absci had an operating margin of -4297.0%, against -10386.5% at Inhibrx Biosciences. Free cash flow was −$94 million at Absci and −$130 million at Inhibrx Biosciences.

Side by side

AbsciInhibrx Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$3M$1M
Revenue growth−38.2%550.0%
Revenue growth a year, last 5 years−10.2%—
Gross margin——
Operating margin−4,297.0%−10,386.5%
Net margin−4,113.7%−10,773.5%
Free cash flow−$94M−$130M
Free cash flow margin−3,358.3%−9,986.5%
Return on capital−162.8%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count24.1%3.4%
Last close$8.45$83.30
P/E at the last close——
Insider trades, last 12 monthsbought $933,174, sold $132,328—
Piotroski F-score3 of 82 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbsciInhibrx Biosciences
Operating margin
Percent of revenue
AbsciInhibrx Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbsciInhibrx Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Absci and Inhibrx Biosciences pages.